Search Results Summary:
-
3A.8 Results of the base-case economic evaluation
Information Requests Calculate the proposed medication cost per patient (Subsection 3A.8.1)Provide a stepped presentation of the cost-effectiveness results, and present the base-case incremental cost
disaggregated discounted costs by resource type for each health state for the intervention and comparator groups. In all models, report the proportions of patients predicted to experience alternative target
pbac.pbs.gov.au/section-3a/3a-8-results-of-the-base-case-economic-evaluation.html
Page last updated: September 2016
-
3A.1 Overview and rationale of the economic evaluation
any alternative perspectives provided as supplementary analyses (Subsection 3A.1.4)For analyses exceeding one year, confirm the discounting methodology for costs and outcomes in the base case (Subsection 3A.1.5
3A.1.5 Discounting
pbac.pbs.gov.au/section-3a/3a-1-overview-and-rationale-of-economic-evaluation.html
Page last updated: September 2016
-
4.2 Estimation of use and financial impact of the proposed medicine
For these calculations, use constant prices, make no allowance for inflation and use a zero discount rate. See the Manual of resource items and their associated costs for further guidance.
Information Requests For an epidemiological approach, use the relevant spreadsheets of the Excel workbook to estimate the number of (Subsection 4.2.1): patients with the medical condition targeted
pbac.pbs.gov.au/section-4/4-2-estimation-of-use-and-financial-impact-of-the-proposed-medicine.html
Page last updated: September 2016
-
Section 4 Use of the medicine in practice
In contrast to the economic evaluation presented in Section 3 of the submission, these financial analyses exclude health outcomes, do not use discounting, and exclude any resource item or copayment
An epidemiological approach estimates the number of people with the medical condition, and then estimates the use of the proposed medicine (see Subsection 4.2) and of other medicines (see Subsection
pbac.pbs.gov.au/section-4-use-of-the-medicine-in-practice.html
Page last updated: September 2016
-
P3.3 Economic evaluation (Section 3)
process has attempted to validate the duration of vaccine effectiveness and any herd immunity assumptions (Subsection 3A.7)Include sensitivity analyses of alternative discounting approaches and scenario
Note that sensitivity analyses using alternative discount rates may be particularly relevant for cost-effectiveness models of vaccines.
pbac.pbs.gov.au/product-type-3/p3-3-economic-evaluation-section-3.html
Page last updated: September 2016
-
Appendix 6 Including nonhealth outcomes in a supplementary analysis
provide details of the method used and its assumptions discount appropriately any productivity changes anticipated beyond one year address each of the assumptions listed above when estimating
pbac.pbs.gov.au/appendixes/appendix-6-including-nonhealth-outcomes-in-a-supplementary-analysis.html
Page last updated: September 2016
-
5.4 Basis for any claim for the ‘rule of rescue’
No alternative exists in Australia to treat patients with the specific circumstances of the medical condition meeting the criteria of the restriction. This means that there are no nonpharmacological
or pharmacological interventions for these patients. The medical condition defined by the requested restriction is severe, progressive and expected to lead to premature death. The more severe the condition
pbac.pbs.gov.au/section-5/5-4-basis-for-any-claim-for-the-rule-of-rescue.html
Page last updated: September 2016
-
3A.9 Uncertainty analysis: model inputs and assumptions
of valuesIncremental outcomesIncremental costsICERDescription of impact on ICER Base case [base case][base case][base case] Discounting rateOutcomes and costs = 5%Outcomes and costs = 3.5% Outcomes and costs
pbac.pbs.gov.au/section-3a/3a-9-uncertainty-analysis-model-inputs-and-assumptions.html
Page last updated: September 2016
-
Product type 4 – Codependent technologies
the population group eligible for that medicine. The Medical Services Advisory Committee (MSAC) classifies such tests as ‘investigative medical services’.
An investigative medical service can have several purposes, 54 of which the following are most likely to be relevant to codependent technologies:
pbac.pbs.gov.au/product-type-4-codependent-technologies.html
Page last updated: September 2016
-
Appendix 1 Expert opinion
Determining an appropriate body of experts will depend on the nature of the information gap that requires filling. Experts may be panels of medical practitioners, a medical specialty group
the proportion of patients with the medical condition that would be eligible according to the requested listing, and predict uptake rates (Subsection 4.2) predict the extent of increases or decreases of other PBS
pbac.pbs.gov.au/appendixes/appendix-1-expert-opinion.html
Page last updated: September 2016
